GSK plc (GSK) To Go Ex-Dividend on May 16th

GSK plc (LON:GSKGet Free Report) declared a dividend on Wednesday, May 1st, Upcoming.Co.Uk reports. Shareholders of record on Thursday, May 16th will be paid a dividend of GBX 15 ($0.19) per share on Thursday, July 11th. This represents a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, May 16th. The official announcement can be seen at this link.

GSK Stock Down 0.4 %

Shares of GSK opened at GBX 1,803 ($22.65) on Tuesday. The company has a current ratio of 0.87, a quick ratio of 0.73 and a debt-to-equity ratio of 134.34. The firm has a market cap of £73.56 billion, a P/E ratio of 1,656.88, a PEG ratio of 1.20 and a beta of 0.27. The stock’s 50 day moving average is GBX 1,673.43 and its two-hundred day moving average is GBX 1,569.49. GSK has a 12 month low of GBX 1,302.60 ($16.36) and a 12 month high of GBX 1,811.25 ($22.75).

Analyst Upgrades and Downgrades

Several brokerages have issued reports on GSK. Shore Capital reaffirmed a “buy” rating on shares of GSK in a research note on Wednesday, May 1st. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,950 ($24.49) price target on shares of GSK in a research report on Wednesday, April 17th. JPMorgan Chase & Co. lifted their price objective on GSK from GBX 1,530 ($19.22) to GBX 1,660 ($20.85) and gave the stock an “underweight” rating in a research report on Thursday, May 2nd. Barclays restated an “equal weight” rating and issued a GBX 1,725 ($21.67) target price on shares of GSK in a report on Tuesday, May 7th. Finally, Berenberg Bank boosted their price target on shares of GSK from GBX 1,650 ($20.72) to GBX 1,820 ($22.86) and gave the company a “buy” rating in a research report on Wednesday, February 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of GBX 1,675.63 ($21.05).

Get Our Latest Stock Analysis on GSK

Insider Activity at GSK

In other news, insider Urs Rohner bought 434 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were acquired at an average price of GBX 1,662 ($20.87) per share, for a total transaction of £7,213.08 ($9,059.38). In other GSK news, insider Urs Rohner purchased 434 shares of GSK stock in a transaction that occurred on Wednesday, March 20th. The stock was purchased at an average price of GBX 1,662 ($20.87) per share, for a total transaction of £7,213.08 ($9,059.38). Also, insider Emma Walmsley sold 139,792 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of GBX 1,658 ($20.82), for a total transaction of £2,317,751.36 ($2,911,016.53). Insiders own 1.77% of the company’s stock.

GSK Company Profile

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

See Also

Dividend History for GSK (LON:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.